Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score

Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score

In patients with advanced hepatocellular carcinoma (HCC) and a baseline α-fetoprotein (αFP) level of 400 ng/mL or more, a survival benefit with second-line ramucirumab therapy was observed for those with Child-Pugh scores of 5 and 6, according to a secondary analysis published in JAMA Oncology.1

The phase 3 REACH trial (A Study of Ramucirumab [IMC-1121B] Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Participants With Hepatocellular Carcinoma After First-Line Therapy With Sorafenib; ClinicalTrials.gov Identifier: NCT01140347) demonstrated a significant difference in progression-free survival between ramucirumab plus best supportive care and placebo plus best supportive care; however, there was no significant difference in overall survival between these 2 treatment arms in unselected patients.

Therefore, researchers sought to evaluate the clinical outcomes associated with post-sorafenib ramucirumab treatment with respect to severity of liver disease and baseline αFP levels.

Results demonstrated a trend toward an overall survival benefit with ramucirumab only for patients with a Child-Pugh score of 5 (hazard ratio [HR], 0.80; 95% CI, 0.63-1.02; P =.06), but no apparent for those with Child-Pugh scores of 6 or 7 and 8.

Researchers found that in patients with baseline αFP levels of 400 ng/mL or greater, a significant survival benefit with ramucirumab was observed for patients with a Child-Pugh score of 5 and 6. Specifically, patients with a Child-Pugh score of 5 had a 39% reduced risk of death (HR, 0.61; 95% CI, 0.43-0.87; P =.01) and those with Child-Pugh 6 had a 36% reduction in the risk of death (HR, 0.64; 95% CI, 0.42-0.98; P =.04) with ramucirumab.

However, there was no significant association between ramucirumab treatment and overall survival for those with Child-Pugh 7 and 8 and baseline αFP levels of 400 ng/mL or more.

In terms of safety, the toxicity profile of ramucirumab was deemed manageable regardless of Child-Pugh score, but patients with Child-Pugh scores of 7 and 8 reported a higher incidence of grade 3 or worse treatment-emergent adverse events in both the ramucirumab and placebo arms compared with those with Child-Pugh scores of 5 or 6.

Ultimately, these findings support the ongoing REACH-2 study (ClinicalTrials.gov Identifier: NCT02435433), which is evaluating ramucirumab compared with placebo in patients with HCC and elevated baseline αFP levels.

Reference

1. Zhu AX, Baron AD, Malfertheiner P, et al. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Analysis of REACH trial results by Child-Pugh score. JAMA Oncol. 2016 Sep 22. doi: 10.1001/jamaoncol.2016.4115. [Epub ahead of print]

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs